Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.

CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to placebo in patients treated with either conventional or moderate ...

Blurting out 'Eureka' in the afternoon of Wednesday, October 8, 2025, indicated how excited I became on receiving a call ...

Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells ...

The Singapore-based parent company of Optus has come under heavy scrutiny after another Australian network outage prevented hundreds of customers from accessing the triple-0 emergency service.

The Central Information Register (CIR) is a computerised system maintained by the Central Bank of Cyprus. It contains information about individuals or legal entities associated with dishonoured ...

The biotech field is no stranger to scientific breakthroughs, but combining novel therapeutic platforms with progressive ...

New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell ...

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to ...

German investigators carried out raids in relation to Northern Data AG, a technology firm backed by Tether Holdings Ltd. The raids relate to an older investigation by Swedish prosecutors into whether ...